Eli Lilly is its nearest rival ... It would allow patients with insulin-dependent diabetes to cover their basal insulin needs with one injection per week, as opposed to once or twice daily.

Additionally, Lilly is launching Rezvoglar (insulin glargine-aglr) injection, a basal insulin that is biosimilar to and interchangeable with Lantus (insulin glargine) injection. Priced at $92 per ...

U-500 insulin human regular (Humulin R U-500, Eli Lilly and Company in the United ... U-500 has prandial and basal time–action profile characteristics. d Basal insulin (glargine, detemir ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a ...

Minnesota Attorney General Keith Ellison is expected to announce a "major development" in the litigation against three large ...

compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in hospitalized general medical patients with type 2 diabetes. The prospective ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company ... range of products comprising of Insulin Human, including Huminsulin ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...